Related Experiment Video
Updated: Oct 9, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.6K
Critically Ill Pediatric Oncology Patients: A Difficult-to-treat Population
1Professor, Department of Critical Care Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Insights
Critically ill pediatric oncology patients represent a challenging group to treat effectively. Their complex conditions require specialized intensive care approaches for improved outcomes.
Area of Science:
- Pediatric critical care medicine
- Pediatric oncology
- Intensive care unit (ICU) management
Background:
- Critically ill pediatric oncology patients present unique management challenges due to their underlying malignancies and treatment toxicities.
- These patients often require intensive care unit (ICU) admission for respiratory failure, sepsis, or other life-threatening complications.
- The intersection of cancer and critical illness in children necessitates a multidisciplinary approach involving oncologists, intensivists, and specialized nurses.
Discussion:
- The management of critically ill pediatric oncology patients is complex, demanding tailored strategies beyond standard pediatric critical care.
- Early recognition of deterioration and prompt intervention are crucial for improving survival rates in this vulnerable population.
- Multifaceted treatment protocols addressing both oncologic emergencies and critical care needs are essential.
Key Insights:
- Pediatric oncology patients in critical condition are a distinct and difficult-to-treat cohort.
- Effective management hinges on understanding the interplay between cancer, its treatment, and critical illness.
- Specialized protocols and expert multidisciplinary care are paramount.
Outlook:
- Further research is needed to optimize treatment strategies and improve outcomes for critically ill pediatric oncology patients.
- Development of evidence-based guidelines for the intensive care of these children is a priority.
- Advancements in supportive care and targeted therapies hold promise for enhancing survival and quality of life.
Abstract:
How to cite this article: Poddar B. Critically Ill Pediatric Oncology Patients: A Difficult-to-treat Population. Indian J Crit Care Med 2021;25(10):1091-1092.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
17
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
17
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
15
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
15
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
15
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
15
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
24
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
24
01:29Drug Dosing: Infants and Children
28
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
28
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K